News and Announcements
Cellmid Limited – Midkine Antibodies Effective in Cancer
- Published October 04, 2013 10:51AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- Anti-midkine antibodies reduce tumour growth and spread
- Anti-angiogenic mechanism of action also evident
- Final studies in the programme to determine Cellmid’s clinical direction
SYDNEY, Thursday, 03 October 2013: Cellmid Limited (ASX: CDY) is pleased to advise that it has now completed its several cancer xenograft efficacy and mechanism of action studies using the company’s lead anti-midkine (MK) antibody with compelling results.
The MK antibody treatment slowed primary tumour growth, reduced cancer spread (metastasis) and slowed the formation of new blood vessels (angiogenesis) in different tumour types. These findings complete the Company’s extensive preclinical programme to determine clinical direction for its MK antibodies.
The findings of the current studies have been consistent with the results published recently by an independent research group (Hao, et al. Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer (2013) http://www.ncbi.nlm.nih.gov/pubmed/23976985)and add to the growing evidence of midkine’s importance in cancer.
To read the full ASX Release please click on the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
